PAPER Garcia-Ratés S, Lewis M, Worrall R, Greenfield S

Additive toxicity of β-amyloid by a novel bioactive peptide in vitro: possible implications for Alzheimer's disease.

PLoS One. 2013;8(2):e54864. PubMed: 23390503

PAPER Vergara X, Kheifets L, Greenland S, Oksuzyan S, Cho YS, Mezei G

Occupational exposure to extremely low-frequency magnetic fields and neurodegenerative disease: a meta-analysis.

J Occup Environ Med. 2013 Feb;55(2):135-46. PubMed: 23389409

PAPER Jelic V, Hagman G, Yamamoto NG, Teranishi Y, Nishimura T, Winblad B, Pavlov PF

Abnormal Platelet Amyloid-β Protein Precursor (AβPP) Metabolism in Alzheimer's Disease: Identification and Characterization of a New AβPP Isoform as Potential Biomarker.

J Alzheimers Dis. 2013 Jan 1;35(2):285-95. PubMed: 23388171

PAPER Resende R, Marques SC, Ferreiro E, Simões I, Oliveira CR, Pereira CM

Effect of α-synuclein on amyloid β-induced toxicity: relevance to lewy body variant of Alzheimer disease.

Neurochem Res. 2013 Apr;38(4):797-806. PubMed: 23389658

PAPER Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall AE, Carter SF, Schöll M, Choo IH, Nordberg A, Scheltens P, Frisoni GB

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease.

Neurology. 2013 Mar 12;80(11):1048-56. Epub 2013 Feb 6 PubMed: 23390179

PAPER Hebert LE, Weuve J, Scherr PA, Evans DA

Alzheimer disease in the United States (2010-2050) estimated using the 2010 census.

Neurology. 2013 May 7;80(19):1778-83. PubMed: 23390181

PAPER Knopman DS

Alzheimer disease biomarkers and insights into mild cognitive impairment.

Neurology. 2013 Mar 12;80(11):978-80. PubMed: 23390186

Boris Rogelj on RNA Twist: C9ORF72 Intron Expansion Makes Aggregating Protein

COMMENT This paper represents an important step in understanding the molecular processes in FTLD/ALS, and expands the basic concepts of biological processes. Furthermore, the dipeptide repeat (DPR) protein antibodies will provide a powerful research and diagnosti

Christopher E. Pearson on RNA Twist: C9ORF72 Intron Expansion Makes Aggregating Protein

COMMENT This report shows an unusual form of biochemistry that contributes to certain forms of ALS/FTLD. Typically, DNA is transcribed to make an RNA, and the RNA is translated to make a protein. This translation almost always requires a signal that says “Transla

PAPER Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, Rogelj B, Al-Chalabi A, Hortobágyi T, Shaw CE

p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.

Acta Neuropathol. 2011 Dec;122(6):691-702. PubMed: 22101323

Agneta Nordberg on Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease.

COMMENT More and more, it is realized that the structural changes (volume losses) in the brain leading to Alzheimer's disease are preceded by more subtle but significant brain changes. Here, the authors show that, since stable MCI (sMCI) patients showed simi

Christopher E. Pearson

The Hospital for Sick Children
Toronto, Canada

RNA Twist: C9ORF72 Intron Expansion Makes Aggregating Protein

RESEARCH NEWS 2013-02-08 Research News Since the identification of the major amyotrophic lateral sclerosis and frontotemporal lobar degeneration gene C9ORF72 more than a year ago, scientists have been hunting for clues as to how it promotes disease. Being an expanded hexanucleoti

Research Brief: Octapharma IVIg Iffy in Phase 2 Trial

RESEARCH NEWS 2013-02-08 Research News Aside from a reasonable safety profile, the first published Phase 2 study of a blood-derived antibody preparation to treat Alzheimer’s disease looks inconclusive at best. The six-month dose-finding trial of Octapharma AG’s intravenous immuno

Harvard Secures $100M to Study Brain Trauma, Other Football Injuries

COMMUNITY NEWS 2013-02-08 Community News The National Football League Players Association (NFLPA) recently announced that it chose Harvard University to lead a $100 million research effort to study chronic traumatic encephalopathy and a host of other devastating health problems in